All In Biotech

Drug Trial Radar · NCT05541107

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3

Last checked: Nov 20, 2026Latest source record: Sep 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

270

Planned (sponsor's estimate)

Start

Jan 2023

Primary completion

Oct 2024

Study completion Jan 2025

Sponsor

Sponsor type
Industry
Collaborators
University of Minnesota
First posted
Sep 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pivotal, confirmatory trial seeks to independently verify the results observed in the EnACT Phase II Stage 2 trial (MB-70007).

Conditions

  • Cryptococcal Meningitis

Interventions

  • MAT2203Drug

    oral lipid nanocrystal amphotericin B

  • Amphotericin BDrug

    Intravenous Amphotericin B

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SurvivalTime frame: 2 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.